Aprea Therapeutics, Inc. Common stock (APRE) Dividend History

Company News

• Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

  Aprea Therapeutics reported progress in its clinical trials for ATRN-119 and APR-1051, with early evidence of anti-tumor activity and continued enrollment. The company has sufficient cash runway into early Q2 2026.

  GlobeNewswire Inc.
• Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

  Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape

  GlobeNewswire Inc.
• Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

  APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor

  GlobeNewswire Inc.
• Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

  ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential

  GlobeNewswire Inc.
• Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

  DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that management will attend the 2024 RBC Capital Markets Global Healthcare Conference that will take place May 14-15, 2024 in New York, NY. Details are as follows:

  GlobeNewswire Inc.